Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Survival analysis and prognostic factors in advanced NSCLC harboring EGFR PACC mutations: A multicenter retrospective study.

Lung cancer (Amsterdam, Netherlands) - 1 Apr 2026

Zhang Qian, Sun Jing, Yang Yehao, Xu Binhao, Wang Yafei, Zhu Yuzhou, Wei Tianyi, Xue Hedong

Abstract excerpt

BACKGROUND: Epidermal growth factor receptor (EGFR) P-loop and αC-helix compression (PACC) mutations represent a distinct subset of uncommon EGFR mutations in non-small cell lung cancer (NSCLC). Although recent trials have explored the efficacy of high-dose furmonertinib and other EGFR tyrosine kinase inhibitors (TKIs) in this population, the real-world evidence regarding overall survival (OS) and prognostic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Prognosis

Share to Protein Kinase Inhibitors

Share to Survival Analysis

Source

Identifiers

PMID: 41747608
DOI: 10.1016/j.lungcan.2026.109341

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survival analysis and prognostic factors in advanced NSCLC harboring EGFR PACC mutations: A multicenter retrospective study.PMID 41747608Read ↗

Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer.Semantic proximity Read ↗

Aggressive Progression to EGFR Tyrosine Kinase inhibitors in Advanced NSCLC Patients: Concomitant Mutations, Prognostic Indicator and Subsequent ManagementSemantic proximity Read ↗

Clinical characteristics and treatment of EGFR exon 19 L747 mutation in advanced NSCLC: a retrospective study.Semantic proximity Read ↗

Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management.Semantic proximity Read ↗

Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.Semantic proximity Read ↗

Epidermal growth factor receptor compound and concomitant mutations: advances in precision treatment strategies.Semantic proximity Read ↗

KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status.Semantic proximity Read ↗

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.Semantic proximity Read ↗

Comprehensive molecular profiling of advanced NSCLC in Greek patients:A prospective HeCOG study.Semantic proximity Read ↗

Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World StudySemantic proximity Read ↗

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study.Semantic proximity Read ↗

Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.